Date: 2015-11-03
Type of information: Series B financing round
Company: Solid GT (USA - MA)
Investors: Biogen (USA - MA) Perceptive Advisors (USA - NY) Janus Capital Management (USA - CO) private advisors
Amount: $42.5 million
Funding type: series B financing round
Planned used: Founded in 2014, Solid GT is a subsidiary of Solid Biosciences. The company is a gene therapy platform focused on developing
novel, disease-modifying therapeutics for Duchenne muscular dystrophy. The company’s licensed technology has demonstrated
efficacy in various DMD animal models and lead candidates are currently undergoing IND-enabling studies. The funds will be used to advance the development of this novel gene therapy platform.
Others: * On November 3, 2015, Solid GT has completed a $42.5m first closing Series B round of financing which the company will use to advance the development of its novel gene therapy platform for Duchenne muscular dystrophy (DMD).The round was led by Perceptive Advisors, LLC and Biogen Inc together with funds managed by Janus Capital Management LLC and private investors. As part of the transaction, Perceptive’s Adam Stone and Biogen’s Lynne Sullivan will join Solid GT’s board of directors.
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
